Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2013

CST Licenses NSCLC Dx Technology to Cepheid

  • Danvers, MA-based Cell Signaling Technology (CST) has granted molecular diagnostics firm Cepheid a nonexclusive license to its patent for a method to detect gene rearrangements of anaplastic lymphoma kinase (ALK), used in PCR-based tests. Financial terms were not disclosed.

    Using CST technology, Cepheid will be developed a test to detect ALK gene rearrangements in patients with non-small-cell lung cancer (NSCLC), the IP-granting firm said. According to CST, preliminary research has shown that approximately 3% to 5% of NSCLC tumors show ALK rearrangements. Along with one of its partners, CST said it holds the majority of IP rights for methods to detect EML4-ALK translocation in cancer cells.

    "We are very pleased with the fact that the cooperation of the Cepheid, in which we will develop molecular research and diagnostic solutions for the detection of fusion gene EML4-ALK,” Michael J. Comb, Ph.D., CST president and CEO, said in a statement. “We believe that it is the logical step associated with the development of our portfolio of patents and research in the field of improving the detection of EML4-ALK expression that enable more effective diagnosis and treatment of cancer patients.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »